The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ESMO WCGIC 2020 | KEYNOTE-966: pembrolizumab, gemcitabine and cisplatin for CCA

Name: KEYNOTE-966: pembrolizumab, gemcitabine and cisplatin for CCA
Uploaded: 2020-07-09T00:00:00Z
Duration: 3 min 39 s
Description: Arndt Vogel, MD, Hannover Medical School, Hanover, Germany, discusses the rationale and study design of the KEYNOTE-966 trial (NCT04003636), evaluating pembrolizumab, gemcitabine and cisplatin in cholangiocarcinoma (CCA) patients. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Arndt Vogel • 9 Jul 2020

ESMO WCGIC 2020

Bile Duct Cancer Gastrointestinal Cancer Antibodies Cisplatin Gemcitabine Pembrolizumab

ABC-06 KEYNOTE-966

Arndt Vogel, MD, Hannover Medical School, Hanover, Germany, discusses the rationale and study design of the KEYNOTE-966 trial (NCT04003636), evaluating pembrolizumab, gemcitabine and cisplatin in cholangiocarcinoma (CCA) patients. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Disclosures

Arndt Vogel, MD has had a speaker, consultancy and advisory role at Amgen, Roche, Bayer, Sanofi, BMS, Lilly, Novartis, EISAI, AstraZeneca, Merck, Incyte, Ipsen, PierreFabre, MSD, Sirtex, BTG, Servier, and Terumo.